Cargando…
Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study
OBJECTIVE: We aimed to evaluate the safety and efficacy of a fixed-dose combination (FDC) of tramadol and diclofenac versus a standard approved FDC of tramadol and paracetamol, in patients with acute moderate to severe pain. METHODS: A total of 204 patients with moderate to severe pain due to acute...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140236/ https://www.ncbi.nlm.nih.gov/pubmed/25152629 http://dx.doi.org/10.2147/JPR.S67817 |
_version_ | 1782331491146006528 |
---|---|
author | Chandanwale, Ajay S Sundar, Subramanian Latchoumibady, Kaliaperumal Biswas, Swati Gabhane, Mukesh Naik, Manoj Patel, Kamlesh |
author_facet | Chandanwale, Ajay S Sundar, Subramanian Latchoumibady, Kaliaperumal Biswas, Swati Gabhane, Mukesh Naik, Manoj Patel, Kamlesh |
author_sort | Chandanwale, Ajay S |
collection | PubMed |
description | OBJECTIVE: We aimed to evaluate the safety and efficacy of a fixed-dose combination (FDC) of tramadol and diclofenac versus a standard approved FDC of tramadol and paracetamol, in patients with acute moderate to severe pain. METHODS: A total of 204 patients with moderate to severe pain due to acute musculoskeletal conditions (n=52), acute flare of osteoarthritis (n=52), acute flare of rheumatoid arthritis (n=50), or postoperative pain (n=50) were enrolled in the study at baseline. Each disease category was then randomized to receive either of two treatments for 5 days: group A received an FDC of immediate-release tramadol hydrochloride (50 mg) and sustained-release diclofenac sodium (75 mg) (one tablet, twice daily), and group B received an FDC of tramadol hydrochloride (37.5 mg) and paracetamol (325 mg) (two tablets every 4–6 hours, up to a maximum of eight tablets daily). The primary efficacy end points were reductions in pain intensity from baseline at day 3 and day 5 as assessed by a Visual Analog Scale (VAS) score. RESULTS: Group A showed a significant reduction in the VAS score for overall pain from baseline on day 3 (P=0.001) and day 5 (P<0.0001) as compared with group B. The combination of tramadol-diclofenac resulted in few mild to moderate adverse events (nausea, vomiting, epigastric pain, and gastritis), which required minimal management, without any treatment discontinuation. The number of adverse events in group A was nine (8.82%) compared with 22 (21.78%) in group B, after 5 days of treatment. CONCLUSION: An FDC of tramadol-diclofenac showed a significantly greater reduction in pain intensity and was well tolerated compared with tramadol-paracetamol, resulting in better analgesia in patients suffering from moderate to severe pain due to acute musculoskeletal conditions, postoperative pain following orthopedic surgery, or acute flare of osteoarthritis and rheumatoid arthritis. |
format | Online Article Text |
id | pubmed-4140236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41402362014-08-22 Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study Chandanwale, Ajay S Sundar, Subramanian Latchoumibady, Kaliaperumal Biswas, Swati Gabhane, Mukesh Naik, Manoj Patel, Kamlesh J Pain Res Original Research OBJECTIVE: We aimed to evaluate the safety and efficacy of a fixed-dose combination (FDC) of tramadol and diclofenac versus a standard approved FDC of tramadol and paracetamol, in patients with acute moderate to severe pain. METHODS: A total of 204 patients with moderate to severe pain due to acute musculoskeletal conditions (n=52), acute flare of osteoarthritis (n=52), acute flare of rheumatoid arthritis (n=50), or postoperative pain (n=50) were enrolled in the study at baseline. Each disease category was then randomized to receive either of two treatments for 5 days: group A received an FDC of immediate-release tramadol hydrochloride (50 mg) and sustained-release diclofenac sodium (75 mg) (one tablet, twice daily), and group B received an FDC of tramadol hydrochloride (37.5 mg) and paracetamol (325 mg) (two tablets every 4–6 hours, up to a maximum of eight tablets daily). The primary efficacy end points were reductions in pain intensity from baseline at day 3 and day 5 as assessed by a Visual Analog Scale (VAS) score. RESULTS: Group A showed a significant reduction in the VAS score for overall pain from baseline on day 3 (P=0.001) and day 5 (P<0.0001) as compared with group B. The combination of tramadol-diclofenac resulted in few mild to moderate adverse events (nausea, vomiting, epigastric pain, and gastritis), which required minimal management, without any treatment discontinuation. The number of adverse events in group A was nine (8.82%) compared with 22 (21.78%) in group B, after 5 days of treatment. CONCLUSION: An FDC of tramadol-diclofenac showed a significantly greater reduction in pain intensity and was well tolerated compared with tramadol-paracetamol, resulting in better analgesia in patients suffering from moderate to severe pain due to acute musculoskeletal conditions, postoperative pain following orthopedic surgery, or acute flare of osteoarthritis and rheumatoid arthritis. Dove Medical Press 2014-08-12 /pmc/articles/PMC4140236/ /pubmed/25152629 http://dx.doi.org/10.2147/JPR.S67817 Text en © 2014 Chandanwale et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Chandanwale, Ajay S Sundar, Subramanian Latchoumibady, Kaliaperumal Biswas, Swati Gabhane, Mukesh Naik, Manoj Patel, Kamlesh Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study |
title | Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study |
title_full | Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study |
title_fullStr | Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study |
title_full_unstemmed | Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study |
title_short | Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study |
title_sort | efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a phase iii, 5-day open-label study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140236/ https://www.ncbi.nlm.nih.gov/pubmed/25152629 http://dx.doi.org/10.2147/JPR.S67817 |
work_keys_str_mv | AT chandanwaleajays efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy AT sundarsubramanian efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy AT latchoumibadykaliaperumal efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy AT biswasswati efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy AT gabhanemukesh efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy AT naikmanoj efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy AT patelkamlesh efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy |